Lithium decreases VEGF mRNA expression in leukocytes of healthy subjects and patients with bipolar disorder

✍ Scribed by Kumiko Kikuchi; Jun-ichi Iga; Sumiko Tayoshi; Masahito Nakataki; Shinya Watanabe; Shusuke Numata; Tetsuro Ohmori

• Publisher: John Wiley and Sons
• Year: 2011
• Tongue: English
• Weight: 101 KB
• Volume: 26
• Category: Article
• ISSN: 0885-6222
• DOI: 10.1002/hup.1215

✦ Synopsis

Objectives Vascular endothelial growth factor (VEGF) is thought to be involved in the pathophysiology of mood disorders and the target of antidepressants. The aim of this study was to elucidate molecular effects of lithium on VEGF expression by using leukocytes of healthy subjects and patients with bipolar disorder. Methods Eight healthy male subjects participated in the first study. Lithium was prescribed for 2 weeks, enough to reach therapeutic serum concentration. Leukocyte counts and serum lithium concentrations were determined at baseline, at 1-and 2-week medication, and at 2 weeks after stopping medication. VEGF mRNA levels were also examined in nine lithium-treated bipolar patients and healthy controls in the second study. Results In the first study, leukocyte counts were significantly increased at 2 weeks compared with those at baseline and were normalized after 2 weeks. VEGF mRNA levels were significantly decreased at 2 weeks and after 2 weeks compared with those at baseline. Consistent with the first study, VEGF mRNA levels were significantly decreased in the lithium-treated bipolar patients compared with healthy controls. Conclusions Our investigation suggests that VEGF mRNA expression may be useful as a peripheral marker of the effects of lithium.